GT Biopharma GTBP
GT Biopharma: quarterly report for the quarter ended Sep 30, 2017
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0001654954-17-010615
- Document
- 10-Q
- Exhibit 10.1
- Employment agreement with anthony cataldo
- Exhibit 10.3
- Employment agreement with steven weldon
- Exhibit 10.4
- Employment agreement with dr. raymond urbanski
- Exhibit 10.5
- Note conversion agreement
- Exhibit 10.6
- Warrant conversion agreement
- Exhibit 10.7
- Preferred conversion agreement
- Exhibit 10.8
- Amended note conversion agreement
- Exhibit 10.9
- Amended warrant conversion agreement
- Exhibit 10.10
- Amended preferred conversion agreement
Not explained yet; the original is on EDGAR.
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Biovie BIVI public float $8M, Dec 31, 2025
- Talphera TLPH public float $8M, Jun 30, 2025
- TherapeuticsMD TXMD public float $9M, Jun 30, 2025
- Oncotelic Therapeutics OTLC public float $9M, Jun 30, 2025
- Processa Pharmaceuticals PCSA public float $8M, Jun 30, 2025